VENTOLIN Drug Patent Profile

When do Ventolin patents expire, and what generic alternatives are available?

Ventolin is a drug marketed by Glaxosmithkline and is included in seven NDAs.

The generic ingredient in VENTOLIN is albuterol sulfate. There are thirty-eight drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the albuterol sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ventolin

A generic version of VENTOLIN was approved as albuterol sulfate by SUN PHARM INDUSTRIES on December 5^th, 1989.

Summary for VENTOLIN

US Patents:	0
Applicants:	1
NDAs:	7
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	52
Patent Applications:	4,547
Drug Prices:	Drug price information for VENTOLIN
Drug Sales Revenues:	Drug sales revenues for VENTOLIN
What excipients (inactive ingredients) are in VENTOLIN?	VENTOLIN excipients list
DailyMed Link:	VENTOLIN at DailyMed

See drug prices for VENTOLIN

See drug sales revenues for VENTOLIN

Recent Clinical Trials for VENTOLIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Beni-Suef University	PHASE4
University of Alberta	Phase 1
Canisius-Wilhelmina Hospital	Phase 3

See all VENTOLIN clinical trials

US Patents and Regulatory Information for VENTOLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	VENTOLIN	albuterol	AEROSOL, METERED;INHALATION	018473-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Glaxosmithkline	VENTOLIN HFA	albuterol sulfate	AEROSOL, METERED;INHALATION	020983-001	Apr 19, 2001	BX	RX	Yes	Yes
Glaxosmithkline	VENTOLIN	albuterol sulfate	SYRUP;ORAL	019621-001	Jun 10, 1987		DISCN	No	No
Glaxosmithkline	VENTOLIN ROTACAPS	albuterol sulfate	CAPSULE;INHALATION	019489-001	May 4, 1988		DISCN	No	No
Glaxosmithkline	VENTOLIN	albuterol sulfate	SOLUTION;INHALATION	019773-001	Apr 23, 1992		DISCN	Yes	No

Expired US Patents for VENTOLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	VENTOLIN	albuterol sulfate	TABLET;ORAL	019112-002	Jul 10, 1986	3,705,233
Glaxosmithkline	VENTOLIN	albuterol sulfate	SYRUP;ORAL	019621-001	Jun 10, 1987	3,644,353
Glaxosmithkline	VENTOLIN	albuterol sulfate	TABLET;ORAL	019112-002	Jul 10, 1986	3,644,353
Glaxosmithkline	VENTOLIN	albuterol	AEROSOL, METERED;INHALATION	018473-001	Approved Prior to Jan 1, 1982	3,644,353
Glaxosmithkline	VENTOLIN	albuterol sulfate	TABLET;ORAL	019112-001	Jul 10, 1986	3,644,353

International Patents for VENTOLIN

See the table below for patents covering VENTOLIN around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	6713016
United Kingdom	1200886
Israel	68805
Belgium	704037
Norway	831875

VENTOLIN (albuterol) Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

What is Ventolin’s market position by drug type and geography?

Ventolin is the brand name for albuterol (salbutamol), a short-acting beta-2 agonist (SABA) used primarily for asthma and COPD-related reversible bronchospasm. In commercial practice, “Ventolin” competes in a crowded, long-established generics market where brand economics depend on (i) device/formulation mix, (ii) supply continuity, (iii) payer access, and (iv) patent/market exclusivity legacy in specific countries.

Key structural facts shaping its market dynamics:

• Product category: generic-dominated acute bronchodilation (SABA), where clinical differentiation is limited and switching is price-driven.
• Competitive set: multiple licensed albuterol brands and AB-rated generic albuterol across inhalers and nebulized forms (with frequent device-led competition).
• Regulatory environment: uptake depends on local approvals, pharmacovigilance posture, manufacturing continuity, and reimbursement rules more than on new clinical endpoints.

How do regulatory and patent realities drive pricing and volume?

Ventolin has persisted as a brand despite generic entry because the brand can retain demand through specific strengths:

• Device familiarity and channel relationships in major markets.
• Formulation availability that supports tender and formulary decisions where supply stability matters.
• Local exclusivities or transition periods that can keep brand share elevated even after active ingredient patent expiry.

Once full generic penetration occurs, the usual pattern is:

• Margin compression as payers shift to lowest-cost alternatives.
• Share stabilization in segments where clinicians or patients remain anchored to brand devices.
• Pricing volatility around periods of manufacturing disruptions, supply recoveries, and contract rebids.

What are the key demand drivers for Ventolin?

Demand is tied to baseline chronic airway disease prevalence and exacerbation frequency:

• Asthma burden: increases in diagnosed asthma and COPD comorbidity increase inhaler consumption.
• Exacerbation cycles: seasonal peaks (respiratory viral seasons) drive quarterly swings in SABA usage.
• Guideline behavior: even where controller therapy reduces exacerbations, many patients still maintain rescue SABA use, supporting steady demand for inhaled bronchodilation.

What are the key market dynamics shaping competition?

The competitive landscape for Ventolin is not primarily about new pharmacology; it is about channel economics and device-level availability. Core dynamics:

• Generic substitution: usually the dominant force in retail and institutional tendering.
• Device competition: pressurized metered-dose inhalers (pMDIs) versus breath-actuated or nebulized options can shift purchasing behavior even within the same active ingredient.
• Supply and manufacturing continuity: shortages trigger temporary price lifts for brands and certain manufacturers, then unwind when supply normalizes.

Competitive dynamics summary (structural)

Dimension	Primary effect on Ventolin	Typical consequence for revenue
Generic substitution	Drives payer switches	Brand revenue declines unless protected by contracts/formularies
Device and delivery format	Changes patient and provider habits	Revenue mix shifts across inhaler types
Supply continuity	Alters buy-side procurement	Temporary price and volume distortions around shortages
Payer access	Determines reimbursement tiers	Net price compression post-switch

How does Ventolin’s financial trajectory typically evolve across the product lifecycle?

For established SABA brands, the lifecycle shape follows a predictable path once generic penetration accelerates:

1. Pre-expiry / early generic entry: brand still holds pricing power; volume remains high.
2. Post-entry ramp: brand loses share first in competitive channels; price starts falling.
3. Mature generic era: brand revenue becomes mostly a function of device/formulation staying power, contract retention, and sporadic supply shocks.
4. Late-stage stabilization or further decline: brand may show relatively flat but lower nominal revenue with continued share erosion.

Trajectory model used in market assessment (industry-standard for established respiratory brands)

Period	Expected brand outcome	What moves the needle
Early exposure to generics	Gradual volume erosion	Switching by payers and distributors
Full penetration	Material margin pressure	Net pricing down; marketing spend rises to defend share
Mature era	Revenue stabilizes at lower base	Contract/formulary stickiness and supply issues
Supply disruption windows	Short-term revenue spikes	Allocation, shortage pricing, and delayed substitution

What do historical commercial patterns suggest about Ventolin’s sales shape?

Ventolin’s commercial pattern is characteristic of long-established off-patent respiratory assets:

• Nominal sales tend to decline or flatten after generic substitution.
• Unit demand (inhalations or prescriptions) often remains relatively steady because SABA use is entrenched as rescue therapy.
• Revenue is more sensitive to net price changes than to dramatic volume changes, because competition is price-led.

Where does financial performance risk concentrate?

Even for a mature brand, financial outcomes can swing due to:

• Manufacturing and supply risk: allocation decisions by distributors can create revenue volatility.
• Regulatory actions: quality-related manufacturing holds change shipment timing.
• Channel contracting cycles: tender rebids can quickly shift share.
• Therapeutic competition: while Ventolin is a rescue medication, inhaler adoption patterns and broader respiratory portfolio decisions can affect procurement.

How does brand-to-generic migration affect revenue elasticity?

SABA demand is relatively inelastic in terms of patient need, but brand revenue is elastic to:

• Net price reductions after payer switches.
• Formulary placement (preferred versus non-preferred).
• Device procurement rules in institutional settings.

So Ventolin often behaves like:

• Stable underlying market demand
• Volatile brand monetization under aggressive generic contracting

What is the investment-relevant outlook for Ventolin?

The investment-relevant view is that Ventolin is unlikely to regain SABA-level pricing power through meaningful clinical differentiation. The more realistic upside lever is channel defense:

• Maintaining device and formulation availability where contracts favor continuity.
• Capturing supply allocation periods.
• Protecting net price via targeted contracts and packaging/device positioning.

Downside is concentrated in:

• Further formulary erosion in major markets.
• Continued price pressure through generic penetration.
• Manufacturing disruptions that impair supply continuity.

What product and channel mix issues matter most to future financial trajectory?

Ventolin’s future trajectory depends on mix decisions that influence procurement:

• Inhaler format: pMDI versus alternative inhaler or nebulized presentations.
• Packaging and device economics: unit cost and how payers compare “equivalent” formats.
• Institutional versus retail: institutional tenders usually enforce aggressive price competition.

Mix-to-financial mapping

Mix lever	Channel where it matters	Expected direction of impact
Device format	Institutional tenders, formularies	Shifts share across equivalent therapy options
Supply allocation	Distribution and acute procurement	Drives short-term revenue volatility
Net price and rebates	All channels	Primary driver of margin and revenue slope

Can Ventolin show growth in a mature, generics-driven market?

Growth in a mature SABA category is typically narrow and episodic, driven by:

• Supply shocks that temporarily reduce low-cost competitors’ availability.
• Short-term formulary changes that restore preferred status.
• Increased seasonal rescue demand in certain geographies.

Sustained multi-year growth typically requires:

• Contractual protection that preserves net price
• Or a structural shift in device adoption that favors a brand procurement position

Key Takeaways

• Ventolin’s market dynamics are dominated by generic substitution, net price compression, and device-level procurement behavior rather than by novel clinical differentiation.
• The financial trajectory is best modeled as stable underlying SABA demand with brand revenue erosion risk, punctuated by short-term spikes from supply allocation and seasonal demand.
• Investment and R&D resource decisions should treat Ventolin as a mature channel-defense asset where margin and revenue are driven mainly by contract retention, device/formulation mix, and manufacturing continuity.
• The largest operational risks that translate into financial outcomes are supply continuity, regulatory manufacturing actions, and payer/tender rebids.

FAQs

1. What drives Ventolin sales most: volume or price?
   Brand revenue is typically more sensitive to net price and payer placement than to underlying patient need.

2. What competitive force is strongest for Ventolin?
   Generic albuterol substitution through formularies and tenders.

3. How do seasonal patterns affect Ventolin financials?
   Rescue inhaler demand rises during respiratory viral seasons, creating quarterly demand swings while brand monetization still tracks net price pressure.

4. Does Ventolin have realistic long-term growth levers?
   Growth is usually defensive and episodic unless contracts preserve net pricing or device procurement shifts structurally in the brand’s favor.

5. Where can brand revenue spike even in a generics era?
   Supply shortages or allocation constraints affecting competing manufacturers can temporarily lift brand revenue.

---

References

[1] FDA. “Albuterol Sulfate Inhalation Aerosol (CFR label / product information context).” U.S. Food and Drug Administration. https://www.fda.gov
[2] GlobalData. “Asthma and COPD market dynamics: SABA (albuterol/salbutamol) and inhaler competition.” GlobalData. https://www.globaldata.com
[3] IQVIA. “Respiratory medicines market access and substitution dynamics (SABA category).” IQVIA. https://www.iqvia.com
[4] WHO. “Asthma and COPD fact sheets and respiratory disease burden references.” World Health Organization. https://www.who.int
[5] GSK. “Ventolin (albuterol) product information and prescribing information resources.” GSK. https://www.gsk.com